Research
Antibody

ScFv/antibody highly specific for disease-modified collagen II used for targeted therapy of arthritic joints

Description and applications

Unique ScFv/antibody highly specific for disease-modified collagen II (found in arthritis patients) has been used to facilitate targeted delivery of therapy to arthritic joints. A fusion construct with mTNFR2-Fc (mouse version of Etanercept) significantly increased efficacy over mTNFR2-Fc alone (p<0.001). Another construct with using viral IL-10 (novel MoA) also provided significant reduction in disease (p=0.0048).

Publications

http://www.arthritis-research.com/content/pdf/ar4613.pdf

Keywords

Rheumatoid arthritis, antibody, therapy

Dr Ahuva Nissim

William Harvey Institute

Want access?

Get in touch with the Business Development Office smd-qmbusiness@qmul.ac.uk